Abby Hardy, Author at BioTuesdays

Developments

Outlook Therapeutics completes enrollment in Phase 3 wet AMD trial

Outlook Therapeutics (NASDAQ:OTLK) completed patient enrollment in its Phase 3 clinical trial comparing ONS-5010 to ranibizumab for the treatment of wet age-related macular degeneration (AMD). Administered via...

August 20, 2019

Developments

Myovant Sciences completes recruitment for Phase 3 endometriosis study

Myovant Sciences (NASDAQ:MYOV) completed patient recruitment for its first of two Phase 3 studies of relugolix combination therapy for the treatment of endometriosis-associated pain. Relugolix is a once daily, oral...

August 20, 2019

Markets

Analysts start Castle Biosciences at buy and OP with PTs of $25-to-$28

Analysts for SVB Leerink, BTIG and Canaccord Genuity launched coverage of Castle Biosciences (NASDAQ:CSTL), saying the company answers a large unmet need in skin cancer. The stock closed at $20.25 on Aug. 16. SVB...

August 19, 2019

Markets

HCW cuts Trillium Therapeutics to neutral and removes PT

H.C. Wainwright downgraded Trillium Therapeutics (NASDAQ:TRIL) to “neutral” from “buy” and removed its price target, saying the precipitous fall in the stock price could lead to a cash crunch. Over the last six months...

August 19, 2019

Developments

Profound Medical gets FDA clearance to market TULSA-PRO for the treatment of prostate disease

Profound Medical (TSX:PRN; OTCQX:PRFMF) received FDA clearance to market TULSA-PRO for the ablation of prostate tissue, with an FDA label allowing U.S. surgeons to perform procedures on both malignant and benign tissue...

August 16, 2019

Executive Moves

Profound Medical names senior finance executive, Steve Forte, to board

Steve Forte Profound Medical (TSX:PRN; OTCQX:PRFMF) appointed seasoned cross-border finance leader, Steve Forte, as a director and member of the board’s audit committee. Most recently, Mr. Forte was CFO of Clementia...

August 15, 2019

Developments

Hepion Pharma doses first HBV patient in 28-day study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) has dosed the first hepatitis B virus (HBV) patient in a 28-day multiple ascending dose clinical trial of CRV431. The trial will assess the safety, tolerability and pharmacokinetics...

August 14, 2019

Developments

Kadmon Holdings completes enrollment for registrational GvHD trial

Kadmon Holdings (NYSE:KDMN) completed enrollment for its registrational trial of KD025 for the treatment of chronic graft-versus-host disease (cGVHD). cGvHD is a deadly complication of hematopoietic stem cell...

August 14, 2019

Markets

HCW starts Mustang Bio at buy; PT $7

H.C. Wainwright initiated coverage of Mustang Bio (NASDAQ:MBIO) with a “buy” rating and $7 price target. The stock closed at $2.89 on Aug. 12. Analyst Joseph Pantginis writes that Mustang is developing multiple novel...

August 13, 2019

Markets

WB starts Phreesia at OP

William Blair launched coverage of Phreesia (NYSE:PHR) with an “outperform” rating. The stock closed at $27.37 on Aug. 9. Phreesia, which went public in July 2019, gives healthcare organizations a suite of robust...

August 12, 2019

Author - Abby Hardy

Myovant Sciences completes recruitment for Phase 3 endometriosis study

Analysts start Castle Biosciences at buy and OP with PTs of $25-to-$28

HCW cuts Trillium Therapeutics to neutral and removes PT

Profound Medical gets FDA clearance to market TULSA-PRO for the treatment of prostate disease

Profound Medical names senior finance executive, Steve Forte, to board

Hepion Pharma doses first HBV patient in 28-day study of CRV431

Kadmon Holdings completes enrollment for registrational GvHD trial

HCW starts Mustang Bio at buy; PT $7

WB starts Phreesia at OP

Subscribe